Universitaetsklinikum Essen AöR — Sponsor Intelligence | 10 EU Trials

Filter these 10 trials by condition, phase, country and more.

Open in Search →

10 Registered trials

2 Recruiting

5 Completed trials

3 Countries active

11 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase II

Phase I/II

Phase I (Other)

Phase III: 2 Phase II/III: 2 Phase II: 4 Phase I/II: 1 Phase I (Other): 1

Oversight events:

2 temporary halts across 2 trials

View oversight register →

100%

5 of 5 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 1 Prostate cancer 1

Top IMPs

LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN 2 NIVOLUMAB 2 (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE 1 AMIVANTAMAB 1 ATEZOLIZUMAB 1 BEVACIZUMAB 1 DURVALUMAB 1 GOZETOTIDE 1 IPILIMUMAB 1 RELATLIMAB 1 TACROLIMUS 1

All trials

10 total

68Ga-FAPI-46 PET for imaging of gastrointestinal cancers: A prospective interventional single-arm clinical trial (FAPI-PET-GI) Pending

2023-506030-70-00 Phase II/III 1 country (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHY…
PSMA PET For intermediate- or high-risk prostate cancer prior to RadioTherapY: A prospective interventional randomized clinical trial (P4RTY… Pending

2023-506032-33-00 Phase III 1 country GOZETOTIDE
Preoperative amivantamab or amivantamab and carboplatin/pemetrexed treatment in patients with resectable non-small-cell lung cancer harborin… Recruiting

2023-505662-28-00 Phase II 3 countries AMIVANTAMAB
A Phase I/II Study of Neoadjuvant, Intra-arterial Administration of [177Lu]Lu-PSMA-617 in Subjects with High-risk, Localised or Locally Adva… Recruiting

2022-500838-28-00 Phase I/II 1 country LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN
Adjuvant nivolumab treatment in stage II high-risk melanoma – A randomized, controlled, phase III trial with biomarker-based risk stratifica… Ended

2023-509394-23-00 Phase III 1 country NIVOLUMAB
Prospective Phase-II Trial of induction chemotherapy and chemoradiotherapy plus/minus the PD-L1 antibody durvalumab followed by surgery or d… Ended

2024-513039-26-00 Phase II 1 country DURVALUMAB
Preoperative immunotherapy with atezolizumab (Tecentriq®) and tiragolumab or atezolizumab (Tecentriq®) and bevacizumab (Avastin®) in patient… Halted

2022-503044-40-00 Phase II 1 country ATEZOLIZUMAB; BEVACIZUMAB
Neoadjuvant Lu-PSMA radioligand therapy and Ipilimumab in men with very high-risk prostate cancer (NEPI) Ended

2024-514386-19-00 Phase I (Other) 1 country IPILIMUMAB; LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN
A multi-center interventional study to assess pharmacokinetics, effectiveness and tolerability of prolonged-release Tacrolimus after Paediat… Ended

2024-516608-40-00 Phase II/III 1 country TACROLIMUS
Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinant… Ended

2024-513074-22-00 Phase II 3 countries NIVOLUMAB; RELATLIMAB

Showing 1–10 of 10 trials

← All sponsors A–Z